Skip to main content

Peer Review reports

From: Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G)

Original Submission
9 Apr 2023 Submitted Original manuscript
31 May 2023 Reviewed Reviewer Report
13 Jun 2023 Reviewed Reviewer Report
25 Jun 2023 Author responded Author comments - Naoki Takahashi
Resubmission - Version 2
25 Jun 2023 Submitted Manuscript version 2
3 Jul 2023 Author responded Author comments - Naoki Takahashi
Resubmission - Version 3
3 Jul 2023 Submitted Manuscript version 3
4 Jul 2023 Author responded Author comments - Naoki Takahashi
Resubmission - Version 4
4 Jul 2023 Submitted Manuscript version 4
12 Jul 2023 Reviewed Reviewer Report
15 Jul 2023 Reviewed Reviewer Report
Resubmission - Version 5
Submitted Manuscript version 5
Publishing
20 Jul 2023 Editorially accepted
5 Aug 2023 Article published 10.1186/s12885-023-11199-1

You can find further information about peer review here.

Back to article page